

## Molekulare Diagnostik: der Schlüssel zur zielgerichteten Therapie

## Diagnostic moléculaire: la clé de tout traitement ciblé

### Literatur / Références

- 1 Haferlach T. Labordiagnostik bei Leukämien und Lymphomen. Bremen: UNI-MED Verlag AG, 2011.
- 2 Baerlocher GM, Oppliger Leibundgut E. Molecular analyses for (early) recognition of hematologic diseases – sense and sensibility for molecular analysis: the art of intelligent decision-making. *Therapeutische Umschau Revue therapeutique*. 2010;67(7):349–58.
- 3 Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2011;29(5):495–503.
- 4 Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood*. 2006;108(1):28–37.
- 5 Oppliger Leibundgut E, Porret NA, Abbal C, Darbellay R, Goede JS, Kalberer C, et al. Molecular monitoring of BCR-ABL1 in chronic myeloid leukemia: The International Scale (IS) is established in Switzerland. submitted.
- 6 Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). *Leukemia*. 2012;26(9):2096–102.
- 7 O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. *Blood*. 2007;110(7):2242–9.
- 8 Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2009;27(3):469–71.
- 9 Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. *Leukemia*. 2011;25(2):218–25.
- 10 Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRα and KIT, and against FGFR1-derived fusion kinases. *Leukemia*. 2012;26(7):1693–5.
- 11 Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. *Blood*. 2011;117(10):2935–43.
- 12 Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. *Leukemia research*. 2011;35(9):1143–52.
- 13 Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *The New England journal of medicine*. 2008;358(18):1909–18.
- 14 Oppliger Leibundgut E, Porret NA, Bienz Muggli M, Baumgartner H, Dahlhaus M, Baerlocher GM. Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia. *Annals of Hematology*. 2012;in press.
- 15 Sharma M, Ravandi F, Bayraktar UD, Chiattoni A, Bashir Q, Giralt S, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2011;17(12):1874–7.
- 16 Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Gotze K, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. *Leukemia*. 2012;26:2353–9.
- 17 Haferlach T. Molecular genetics in myelodysplastic syndromes. *Leukemia research*. 2012;36:1459–62.